On April 28th 2026, PTC Therapeutics shared new data from the long-term extension of PIVOT-HD, the Phase 2 clinical trial of ...

Two articles this month took aim at the root cause of HD rather than its downstream consequences. The HTT1a mouse study and the CRISPR study are asking the same fundamental question from different ...

TFC has been formally incorporated into the Unified Huntington’s Disease Rating Scale (UHDRS), which is the standard clinical ...

Apathy in people with Huntington’s disease (HD) isn’t just a lack of interest or motivation, it is a loss of drive, initiative, and emotional responsiveness that affects not only what the person with ...

This month brought landmark therapeutic news, advances in biomarkers, deeper insights into what drives Huntington’s disease (HD), and fresh perspectives on mental health in HD. In particular among the ...

INGREZZA is the trade name of valbenazine, a drug developed by the company Neurocrine Biosciences. It works similarly to tetrabenazine and deutetrabenazine (Austedo), drugs commonly prescribed to help ...

In plain language. Written by scientists. For the global HD community.

In plain language. Written by scientists. ⏱️ 10 min read | The Total Functional Capacity score has been used in Huntington’s disease research for decades. Here’s what it measures, what it misses, & ...

This week, we heard an update from Roche about their huntingtin-lowering therapy, tominersen, currently being tested in the GENERATION HD2 trial. An independent data monitoring committee (iDMC) that ...

Imagine the gene that causes Huntington’s disease (HD) as a vast river. At its source is the CAG repeat – a genetic letter code that dictates how the river will flow. As the river moves downstream, it ...

Juvenile-onset HD is really rare, but a new study has helped us understand what the symptoms are and how they change over time. This is really important and in time will help us work out whether ...